Filing Analysis
Editas Medicine, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing serves as a formal vehicle to furnish the quarterly earnings press release and business highlights to the SEC.
Key Facts
- The report was filed on May 5, 2026, covering the fiscal quarter ended March 31, 2026.
- The company furnished a press release as Exhibit 99.1 detailing results of operations and financial condition.
- The filing was signed by Amy Parison, Chief Financial Officer.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Editas Medicine, Inc. dismissed Ernst & Young LLP and appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026. The transition was approved by the Audit Committee following a formal review process and reported no disagreements or accounting issues.
Key Facts
- Dismissal of Ernst & Young LLP occurred on April 1, 2026.
- PricewaterhouseCoopers LLP was appointed as the new auditor for the fiscal year ending December 31, 2026.
- Ernst & Young's audit reports for the fiscal years ended December 31, 2024, and December 31, 2025, contained no adverse opinions or qualifications.
- There were no 'disagreements' or 'reportable events' as defined by SEC regulations during the fiscal years 2024, 2025, or the subsequent interim period through April 1, 2026.
- The company provided EY with a copy of the disclosure and filed EY's letter of agreement as Exhibit 16.1.
Editas Medicine announced that the U.S. Patent and Trademark Office (USPTO) reaffirmed a prior decision favoring the Broad Institute in a foundational CRISPR/Cas9 patent interference case. This ruling supports the validity of the core intellectual property licensed by Editas for human therapeutic applications against challenges from the University of California and others.
Red Flags
- Potential for further litigation delay as the opposing party (CVC) retains the right to appeal the decision to the CAFC.
Key Facts
- On March 26, 2026, the USPTO reaffirmed the Patent Trial and Appeal Board's (PTAB) decision in favor of the Broad Institute.
- The interference involves patents for CRISPR/Cas9 editing in human cells between CVC (University of California, University of Vienna, and Emmanuelle Charpentier) and the Broad Institute (including MIT and Harvard).
- The decision followed a remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) after a May 2025 ruling.
- CVC retains the right to appeal this reaffirmed decision to the CAFC.
Editas Medicine announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The filing serves as a formal vehicle to furnish the earnings press release and provide business highlights to the public.
Key Facts
- Financial results cover the fiscal quarter and year ended December 31, 2025
- Press release issued and furnished as Exhibit 99.1 on March 9, 2026
- Report signed by Amy Parison, Chief Financial Officer
- The information is furnished under Item 2.02 and not deemed 'filed' for Section 18 purposes